SINGAPORE, March 3, 2026 /PRNewswire/ -- OMOWAY, the pioneer in intelligent mobility, is proud to announce that its self-balancing electric motorcycle, the OMO X, has been honored with the prestigious 2026 iF DESIGN AWARD. The iF DESIGN AWARD is recognized as one of the world's most renowned design honors. Run by the independent iF Design Foundation in Germany, the award has served as a global benchmark for outstanding design excellence and impact for over 70 years.
With its innovative features and visionary design, OMOWAY stood out among nearly 10,000 high-caliber submissions from 68 countries, showcasing the highly competitive nature and significance of winning this award.
As the world's first mass-produced self-balancing electric motorcycle, the OMO X follows the philosophy of "Form Follows Function," seamlessly integrating intelligent hardware, user-centric utility, and avant-garde aesthetics. Its bold geometric lines and minimalist surfaces create a distinct futuristic silhouette. To meet the diverse demands of daily riding, the OMO X features the world's first "Multi-transformable Module," allowing the vehicle to switch between Scooter, Street, and GT modes.
Core Tech: Self-Balancing for Proactive Safety
The OMO X integrates a sophisticated perception-computing and balance-control system, enabling the vehicle to maintain stability during low-speed cruising or temporary stops. This innovation significantly reduces rider fatigue. Based on self-balancing tech, the OMO X further incorporates smart features like ACC (Adaptive Cruise Control), Auto Hold, and Hill Hold Control. By addressing traditional safety hazards such as loss of balance, rolling, and side-slipping, OMOWAY has achieved a paradigm shift from "passive protection" to "active safety".
Upcoming Global Launch of OMO Robot Architecture
Driven by the mission to "deliver innovative smart experiences to every life," OMOWAY will host its Global Tech Launch in Singapore on March 12. The event will officially unveil the proprietary OMO Robot Architecture, showcasing the vast potential of self-balancing technology across multiple scenarios and ushering in a new era of smarter, safer two-wheeled mobility.
Furthermore, OMOWAY's flagship model the OMO-X, has officially entered mass production. The official pre-order window and delivery schedule will be exclusively disclosed during the launch event.
For more information, please follow OMOWAY on social media：Instagram@omoway.
About OMOWAY
OMOWAY is a leading global tech company dedicated to bringing cutting-edge, full-stack auto-grade technology to the two-wheeled mobility sector. We create the next generation of intelligent, safe, and comfortable mobility products.
With the debut of its self-balancing smart electric motorcycle, OMOWAY has already captured the attention of media across 55 countries and regions. Our mission is to deliver innovative smart experiences to every life, driving the global transition toward smarter and more sustainable living through user-oriented technological breakthroughs.
About the iF DESIGN AWARD
Since 1954, the iF DESIGN AWARD has been a globally recognized benchmark of design excellence. The iF Design brand is internationally established as a symbol of outstanding design achievement, with the iF DESIGN AWARD regarded as one of the most important design honors in the world. It honors design achievements in all disciplines: product, packaging, branding & communication, service design, architecture and interior architecture, user experience (UX), user interface (UI) and concepts. All award-winning entries are presented on ifdesign.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
OMOWAY wins 2026 iF DESIGN AWARD; Proprietary Robot Architecture Set for Global Debut
|
In the news release, CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region, issued 02-Mar-2026 by CooperVision, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region
Second Phase of Rollout Builds on Strong Momentum Across Europe and UK.
ROCHESTER, N.Y., March 2, 2026 /PRNewswire/ -- CooperVision is continuing its global rollout of MyDay® MiSight® 1 day contact lenses with immediate availability in Australia and New Zealand, marking the myopia control product's first entry into the Asia Pacific region. In addition, the innovative lenses are now shipping in South Africa, building on the initial launch earlier this year across Europe and the United Kingdom.
The expansions underscore the company's commitment to making evidence-based myopia management interventions accessible to eye care professionals (ECPs) and children worldwide.
"Myopia is a pressing health challenge of epic proportions, now affecting nearly one in three children worldwide," said Debbie Olive, Chief Commercial Officer for CooperVision.*1,2,3 "The growing availability and adoption of our myopia control contact lenses, including MyDay® MiSight® 1 day, are helping drive a meaningful shift in pediatric eye care by supporting children's vision today while helping protect their sight for the future."
MyDay® MiSight® 1 day combines the proven MiSight® 1 day ActivControl® Technology with the advanced silicone hydrogel material used in MyDay® lenses, offering "always-on" myopia control alongside the comfort and performance of a daily disposable silicone hydrogel lens.†4 This technology has demonstrated an approximate 50% reduction in myopia progression and is supported by the longest-running soft contact lens clinical trial for myopia control in children. ‡5,6
"The introduction of MyDay® MiSight® 1 day into the Asia Pacific region marks an important milestone in our global efforts to make the latest in evidence-based myopia control accessible to as many children as possible," said Jennifer Lambert, VP – Myopia Control & Cornea Care for CooperVision, CooperVision. "As MiSight® products become available in more markets worldwide, CooperVision's scale and focus are driving a shift in the paradigm, from simply correcting vision to actively controlling myopia progression."
CooperVision expects to continue its phased MyDay® MiSight® 1 day expansion in the coming months, including additional availability in Asia Pacific markets.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over 50 million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
_________________________________
* Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
† Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.
‡ Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day.
_________________________________
1 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2 Liang J, Pu Y, Chen J, et al, Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis, British Journal of Ophthalmology 2025;109:362-371.
3 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
4 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
5 Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
6 CVI data on file, 2025.
Photo - https://mma.prnasia.com/media2/2922809/CooperVision_MyDay_MiSight_1_day.jpg?p=medium600
Logo - https://mma.prnewswire.com/media/2854596/5829336/CooperVision_Logo.jpg
Correction: The first paragraph has been revised.
In the news release, CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region, issued 02-Mar-2026 by CooperVision, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Second Phase of Rollout Builds on Strong Momentum Across Europe and UK.
ROCHESTER, N.Y., March 2, 2026 /PRNewswire/ -- CooperVision is continuing its global rollout of MyDay® MiSight® 1 day contact lenses with immediate availability in Australia and New Zealand, marking the myopia control product's first entry into the Asia Pacific region. In addition, the innovative lenses are now shipping in South Africa, building on the initial launch earlier this year across Europe and the United Kingdom.
The expansions underscore the company's commitment to making evidence-based myopia management interventions accessible to eye care professionals (ECPs) and children worldwide.
"Myopia is a pressing health challenge of epic proportions, now affecting nearly one in three children worldwide," said Debbie Olive, Chief Commercial Officer for CooperVision.*1,2,3 "The growing availability and adoption of our myopia control contact lenses, including MyDay® MiSight® 1 day, are helping drive a meaningful shift in pediatric eye care by supporting children's vision today while helping protect their sight for the future."
MyDay® MiSight® 1 day combines the proven MiSight® 1 day ActivControl® Technology with the advanced silicone hydrogel material used in MyDay® lenses, offering "always-on" myopia control alongside the comfort and performance of a daily disposable silicone hydrogel lens.†4 This technology has demonstrated an approximate 50% reduction in myopia progression and is supported by the longest-running soft contact lens clinical trial for myopia control in children. ‡5,6
"The introduction of MyDay® MiSight® 1 day into the Asia Pacific region marks an important milestone in our global efforts to make the latest in evidence-based myopia control accessible to as many children as possible," said Jennifer Lambert, VP – Myopia Control & Cornea Care for CooperVision, CooperVision. "As MiSight® products become available in more markets worldwide, CooperVision's scale and focus are driving a shift in the paradigm, from simply correcting vision to actively controlling myopia progression."
CooperVision expects to continue its phased MyDay® MiSight® 1 day expansion in the coming months, including additional availability in Asia Pacific markets.
To find out more about CooperVision's contact lens portfolio and evidence-based myopia management interventions, visit: www.coopervision.com/select-region
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over 50 million lives each year. For more information, please visit www.coopercos.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay® MiSight® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
laura@mcdougallpr.com or +1-585-434-2148
_________________________________
* Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
† Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.
‡ Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day.
_________________________________
1 Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
2 Liang J, Pu Y, Chen J, et al, Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis, British Journal of Ophthalmology 2025;109:362-371.
3 James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest – Reflections on the Implications for Clinical Practice. Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. https://doi.org/10.1167/iovs.62.5.1.
4 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
5 Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
6 CVI data on file, 2025.
Photo - https://mma.prnasia.com/media2/2922809/CooperVision_MyDay_MiSight_1_day.jpg?p=medium600
Logo - https://mma.prnewswire.com/media/2854596/5829336/CooperVision_Logo.jpg
Correction: The first paragraph has been revised.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region
